Bcl-2 and Bcl-X up-regulation upon PECAM-1 homophilic interaction
Cells . | Bcl-2* . | Bcl-X* . |
---|---|---|
CD14+CD34+ before adhesion | 16 ± 10 | 6 ± 2 |
CD14+CD34+ on D12P | 100 ± 11 | 80 ± 13 |
CD14+CD34+on D12P + anti–PECAM-1 F(ab′)2 | 6 ± 3 | 9 ± 2 |
CD14+CD34+ on mock NIH3T3 | 20 ± 4 | 10 ± 2 |
Cells . | Bcl-2* . | Bcl-X* . |
---|---|---|
CD14+CD34+ before adhesion | 16 ± 10 | 6 ± 2 |
CD14+CD34+ on D12P | 100 ± 11 | 80 ± 13 |
CD14+CD34+on D12P + anti–PECAM-1 F(ab′)2 | 6 ± 3 | 9 ± 2 |
CD14+CD34+ on mock NIH3T3 | 20 ± 4 | 10 ± 2 |
Bcl-2 and Bcl-X expression was evaluated by cytoplasmic immunofluorescence in CD14+CD34+ cells before or after 1-hour adhesion on D12P (PECAM-1+) or mock-transfected NIH3T3 monolayers, in the absence or presence of the F(ab′)2 of the specific anti–PECAM-1 mAb (5 μg/mL), collected after an additional 36 hours of culture. Cells were fixed in 2% paraformaldehyde, permeabilized with 0.01% NP-40, stained with the specific FITC anti–Bcl-2 or FITC anti–Bcl-X mAbs, and run on a FACSort. At least 104 cells per sample were analyzed and results plotted as arbitrary units (au) of mean fluorescence intensity (MFI, mean ± SD from 8 experiments). MFI of cells stained with an FITC-irrelevant mAb was 10 ± 5 au.